PMID- 26207169
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150724
LR  - 20240323
IS  - 1948-5182 (Print)
IS  - 1948-5182 (Electronic)
VI  - 7
IP  - 14
DP  - 2015 Jul 18
TI  - Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing 
      cirrhosis and risk of hepatocellular carcinoma.
PG  - 1875-83
LID - 10.4254/wjh.v7.i14.1875 [doi]
AB  - AIM: To assess serum cartilage oligomeric matrix protein (COMP) as a marker of 
      cirrhosis and risk of progression to hepatocellular carcinoma (HCC). METHODS: A 
      COMP enzyme-linked immunosorbent assay was used to test 187 patients with chronic 
      liver diseases at the time point of first evaluation. The selected patients 
      included 72 with chronic hepatitis B infection, 75 with chronic hepatitis C 
      infection, 22 with primary biliary cirrhosis, 7 with autoimmune hepatitis type 1, 
      and 11 with alcoholic liver disease. Demographic, biochemical, histological and 
      clinical characteristics of the patients were recorded at the first evaluation. 
      One hundred and forty-seven patients were followed for a median [interquartile 
      range (IQR)] duration of 96.5 (102) mo. The clinical, biochemical and 
      histological data, as well as the development of cirrhosis, HCC according to 
      internationally accepted criteria and in case of death, a liver-related cause 
      during the follow-up period, were recorded at the electronic database of our 
      clinic. COMP determination was also performed in 43 healthy individuals who 
      served as the control study group. RESULTS: COMP positivity (> 15 U/L) was 
      detected in 22%-36% among chronic liver disease groups. Strikingly, almost 83% of 
      COMP-positive patients were cirrhotic at baseline, independently of cause of 
      liver disease. Among the patients who developed HCC during follow-up, 73.7% 
      (14/19) were COMP positive at baseline. COMP positivity was significantly 
      associated with older age (P < 0.001), advanced fibrosis (P = 0.001) and 
      necroinflammatory activity (P = 0.001), higher aspartate aminotransferase (P < 
      0.001), alanine aminotransferase (P < 0.02), gamma-glutamyl transpeptidase (P = 
      0.003), alkaline phosphatase (P = 0.001), bilirubin (P < 0.05), international 
      normalized ratio (P = 0.002) and alpha-fetoprotein levels (P < 0.02), and lower 
      albumin (P < 0.001), and platelet count (P = 0.008). COMP levels [median (IQR)] 
      were significantly higher in cirrhotics compared to non-cirrhotics [13.8 (7.9) 
      U/L vs 9.8 (4.6) U/L, respectively; P < 0.001]. On multivariate logistic 
      regression analysis, COMP-positivity was independently associated only with 
      cirrhosis (OR = 4.40, 95%CI: 1.33-14.69, P = 0.015). Kaplan-Meier analysis showed 
      that COMP positivity was significantly associated with HCC development (P = 
      0.007) and higher incidence of liver-related death (P < 0.001). CONCLUSION: 
      Elevated COMP levels are strongly associated with cirrhosis and HCC progression. 
      Serum COMP is a new promising non-invasive biomarker for HCC risk assessment in 
      surveillance programs.
FAU - Norman, Gary L
AU  - Norman GL
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Gatselis, Nikolaos K
AU  - Gatselis NK
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Shums, Zakera
AU  - Shums Z
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Liaskos, Christos
AU  - Liaskos C
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Bogdanos, Dimitrios P
AU  - Bogdanos DP
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Koukoulis, George K
AU  - Koukoulis GK
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
FAU - Dalekos, George N
AU  - Dalekos GN
AD  - Gary L Norman, Zakera Shums, Inova Diagnostics, Inc., San Diego, CA 92131, United 
      States.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC4506945
OTO - NOTNLM
OT  - Biomarker
OT  - Cirrhosis
OT  - Enzyme-linked immunosorbent assay
OT  - Hepatic fibrosis
OT  - Hepatocellular carcinoma
OT  - Viral hepatitis
EDAT- 2015/07/25 06:00
MHDA- 2015/07/25 06:01
PMCR- 2015/07/18
CRDT- 2015/07/25 06:00
PHST- 2015/04/14 00:00 [received]
PHST- 2015/05/29 00:00 [revised]
PHST- 2015/06/30 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2015/07/25 06:01 [medline]
PHST- 2015/07/18 00:00 [pmc-release]
AID - 10.4254/wjh.v7.i14.1875 [doi]
PST - ppublish
SO  - World J Hepatol. 2015 Jul 18;7(14):1875-83. doi: 10.4254/wjh.v7.i14.1875.